PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the European Commission has returned the CHMP's negative opinion on Translarna's conditional marketing authorization for re-evaluation. Translarna remains available in Europe pending further review.
May 20, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The European Commission's decision to return the CHMP's negative opinion on Translarna for re-evaluation is positive for PTC Therapeutics. Translarna remains available in Europe, which supports the company's revenue stream.
The decision by the European Commission to return the CHMP's negative opinion for re-evaluation means that Translarna will continue to be available in Europe. This is a positive development for PTC Therapeutics as it maintains a key revenue stream and provides an opportunity for the company to present additional evidence to support the drug's authorization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100